Precision Biosciences (DTIL) Accumulated Expenses (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Accumulated Expenses data on file, last reported at $3.3 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $3.3 million, up 149.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.3 million (up 149.12% YoY), and the FY2025 annual result was $1.7 million, down 66.92% from the prior year.
• Accumulated Expenses grew to $3.3 million in Q1 2026 per DTIL's latest filing, from $1.7 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $5.2 million in Q3 2022 and troughed at $1.2 million in Q1 2024.
• A 5-year average of $2.9 million and a median of $2.5 million in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses slumped 72.99% in 2022, then soared 172.47% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $1.8 million in 2022, then surged by 172.47% to $5.0 million in 2023, then grew by 4.1% to $5.2 million in 2024, then plunged by 66.92% to $1.7 million in 2025, then jumped by 89.96% to $3.3 million in 2026.
• Business Quant data shows DTIL's Accumulated Expenses at $3.3 million in Q1 2026, $1.7 million in Q4 2025, and $1.3 million in Q3 2025.